{"id":23908,"date":"2025-01-29T09:39:00","date_gmt":"2025-01-29T14:39:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=23908"},"modified":"2026-10-07T12:38:31","modified_gmt":"2026-10-07T16:38:31","slug":"breaking-down-the-cost-of-generic-drug-production-understanding-the-factors-influencing-affordability","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/breaking-down-the-cost-of-generic-drug-production-understanding-the-factors-influencing-affordability\/","title":{"rendered":"What It Really Costs to Make a Generic Drug: A Full-Stack Analysis"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

A simple generic tablet needs about $2.43 million in direct development spending and about 58.9 months to move from first API work to FDA approval, according to a model built for the U.S. Department of Health and Human Services. [1] After the model adds failure risk and the cost of capital, the expected cost rises to $5.28 million. [1] The finished product then sells into a market where generics filled 89% of U.S. prescriptions in 2025 and took 11.6% of prescription drug spending. [2]<\/p>\n\n\n\n

This article follows the cost of a generic drug through seven layers, from the first formulation batch to tariff policy. It separates documented facts from our own calculations. Where public data is thin, it says so. We cite DrugPatentWatch as a source for patent and exclusivity context, and we point to primary documents for every number that matters.<\/p>\n\n\n\n

Last updated: October 7, 2026.<\/p>\n\n\n\n

The Short Answer: What Does a Generic Drug Cost to Develop and Sell?<\/strong><\/h2>\n\n\n\n

A generic drug costs between about $2.4 million and more than $45 million to develop, depending on product type. The FDA filing fee alone is $375,684 for fiscal year 2027. [3] Once six or more generic makers compete, the price falls more than 95% below the brand price before generic entry. [4]<\/p>\n\n\n\n

    \n
  • Simple oral generic with a biowaiver: $2,426,899 in direct cost and $5,281,488 in expected, risk-adjusted cost (2020 dollars). [1]<\/li>\n\n\n\n
  • Inhaler with a clinical endpoint bioequivalence study: about $45 million for that one study. [1]<\/li>\n\n\n\n
  • FDA ANDA fee, FY2027: $375,684, plus facility fees that depend on where the product is made. [3]<\/li>\n\n\n\n
  • Price after entry: 39% below the pre-entry brand price with one generic maker, and more than 95% below with six or more (AMP basis). [4]<\/li>\n<\/ul>\n\n\n\n

    No single number answers the question. Cost depends on product type, patent position, and number of competitors at launch.<\/p>\n\n\n\n

    The Seven Findings That Matter<\/strong><\/h2>\n\n\n\n

    Each finding below stands alone. Findings marked “Analysis” contain a figure we calculated from the cited data.<\/p>\n\n\n\n

      \n
    1. The HHS-commissioned model puts the direct cost of a simple oral generic at $2,426,899 and its expected cost, after failure risk and capital cost, at $5,281,488. [1] Analysis: expected cost is 2.18 times the direct cost.<\/li>\n\n\n\n
    2. The FY2027 ANDA fee is $375,684. [3] The FY2025 fee was $321,920. [8] Analysis: the fee rose 16.7% in two fiscal years.<\/li>\n\n\n\n
    3. In the same model, a comparative clinical endpoint bioequivalence study for an inhaler costs about $45 million, based on 900 subjects at $50,000 each. [1] Analysis: that is 36 times the $1.25 million modeled cost of a healthy-volunteer study for the same product type.<\/li>\n\n\n\n
    4. With one generic producer, the generic price is 39% below the pre-entry brand price. With two, 54% below. With four, 79% below. With six or more, more than 95% below (AMP basis, products with first generic entry in 2015 to 2017). [4][12] Analysis: that leaves 61%, 46%, 21%, and under 5% of the brand price.<\/li>\n\n\n\n
    5. In 2025, generics cost about $26.50 per prescription at the reported totals, and brand drugs cost about $1,658. [2] Analysis: the brand figure is 62.6 times the generic figure.<\/li>\n\n\n\n
    6. In 2025, 71% of drugs in shortage were sterile injectables, and the average shortage lasted five years, a record. [5]<\/li>\n\n\n\n
    7. Generic drugs, biosimilars, and their ingredients are excluded from the Section 232 tariffs on patented pharmaceuticals, and Commerce must reassess that exclusion within one year of the April 2, 2026 proclamation. [6]<\/li>\n<\/ol>\n\n\n\n
      \n

      Generics filled 89% of U.S. prescriptions in 2025, about 4 billion of them, and accounted for 11.6% of prescription drug spending, or $106 billion against $804 billion for brand drugs. (Association for Accessible Medicines and IQVIA Institute, 2026) [2]<\/p>\n<\/blockquote>\n\n\n\n

      Methodology: What Data We Used and How We Calculated It<\/strong><\/h2>\n\n\n\n

      Which data sources does this analysis use?<\/strong><\/h3>\n\n\n\n

      We used five groups of sources. First, the HHS\/ASPE report “Cost of Generic Drug Development and Approval” by Eastern Research Group (ERG), dated December 31, 2021. It combines a literature review, interviews with 20 industry organizations, and IQVIA National Sales Perspective data from January 2013 to June 2021. [1] Second, Federal Register notices for GDUFA fees in FY2026 and FY2027. [3][9] Third, FDA’s 2019 analysis of generic prices by number of competitors. [4][12] Fourth, annual savings reports from the Association for Accessible Medicines (AAM) and IQVIA for 2024 and 2025 data. [2][7] Fifth, drug shortage data from the U.S. Pharmacopeia (USP), reported through trade press, and company results from Sandoz. [5][16]<\/p>\n\n\n\n

      How did we calculate derived figures?<\/strong><\/h3>\n\n\n\n

      We used these rules and no others:<\/p>\n\n\n\n

        \n
      • Percent change equals (new value minus old value) divided by old value.<\/li>\n\n\n\n
      • Cost per prescription equals total reported spending divided by total reported prescriptions, using AAM’s rounded counts.<\/li>\n\n\n\n
      • Bioequivalence study cost equals the number of subjects times the per-subject cost in ERG Table 4. It excludes failure risk and capital cost.<\/li>\n\n\n\n
      • Expected-cost multiple equals expected capitalized cost divided by direct cost, both from ERG Table 2.<\/li>\n<\/ul>\n\n\n\n

        We counted each fee, price, and shortage figure once, from the source that reports it first-hand. Where one AAM report repeats another year’s number, we used the number from that year’s own report.<\/p>\n\n\n\n

        What are the limits of this analysis?<\/strong><\/h3>\n\n\n\n

        ERG costs are in 2020 dollars and are model averages, not company accounts. [1] FDA price data covers products with first generic entry in 2015 to 2017. [4] USP figures reach us through a trade-press summary of the USP report, so check the USP report before you quote them. [5] We found no primary public source for per-unit manufacturing cost. We do not invent one.<\/p>\n\n\n\n

        Definitions: Key Terms in Generic Drug Cost Analysis<\/strong><\/h2>\n\n\n\n
          \n
        • ANDA: Abbreviated New Drug Application. The filing a generic maker submits to FDA. It shows the same active ingredient, dosage form, route, and strength as the brand drug, plus bioequivalence. [1]<\/li>\n\n\n\n
        • Reference listed drug (RLD): the brand drug that the generic copies. [1]<\/li>\n\n\n\n
        • Bioequivalence (BE): evidence that the generic acts in the body as the brand drug does, within limits FDA sets. [1]<\/li>\n\n\n\n
        • Biowaiver: FDA permission to skip in vivo BE testing when in vitro tests succeed. [1]<\/li>\n\n\n\n
        • Paragraph IV certification: a statement that a listed brand patent is invalid, unenforceable, or not infringed by the generic. [1]<\/li>\n\n\n\n
        • 180-day exclusivity: the first filer or filers of a substantially complete ANDA with a Paragraph IV certification are generally eligible to market alone against other Paragraph IV filers for 180 days. [1]<\/li>\n\n\n\n
        • Authorized generic (AG): the brand product sold under the brand’s own NDA without a brand label. It can launch during the 180-day period. [1]<\/li>\n\n\n\n
        • Complex generic: a product with a complex active ingredient, formulation, route of delivery, dosage form, or drug-device combination. [1]<\/li>\n<\/ul>\n\n\n\n

          Original framework: the Seven-Layer Cost Stack<\/strong><\/h3>\n\n\n\n

          The Seven-Layer Cost Stack is our own classification. It is not an industry standard. It sorts the cost of a generic drug by where the money goes and rates how well public data covers each layer. The ratings are our judgment.<\/p>\n\n\n\n

          Layer<\/th>What it holds<\/th>Best public measure<\/th>Source<\/th>Public data quality<\/th><\/tr><\/thead>
          1. Development<\/td>API work, formulation, stability, biobatches<\/td>$2.43M direct, $5.28M expected (simple oral)<\/td>[1]<\/td>Strong<\/td><\/tr>
          2. Bioequivalence<\/td>PK, PD, and clinical endpoint studies<\/td>$2,000 to $27,000 per healthy subject; about $45M for an inhaler clinical endpoint study<\/td>[1]<\/td>Moderate<\/td><\/tr>
          3. Regulatory fees<\/td>GDUFA ANDA, DMF, facility, program fees<\/td>ANDA fee $375,684 in FY2027<\/td>[3]<\/td>Strong<\/td><\/tr>
          4. IP and litigation<\/td>Paragraph IV suits, 30-month stays, settlements<\/td>Case outcome shares; cost per case not reported in our sources<\/td>[1]<\/td>Moderate<\/td><\/tr>
          5. Manufacturing and supply<\/td>API, finished dose, sterile capacity, shortages<\/td>Facility fees and shortage data; no unit cost<\/td>[3][5]<\/td>Thin<\/td><\/tr>
          6. Price erosion<\/td>Price decline as competitors enter<\/td>61% to under 5% of pre-entry brand price<\/td>[4]<\/td>Strong<\/td><\/tr>
          7. Policy and trade<\/td>Tariffs, user fee law, exclusivity rules<\/td>Generics excluded from Section 232 tariffs for now<\/td>[6]<\/td>Moderate, changing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          How Much Does It Cost to Develop a Generic Drug?<\/strong><\/h2>\n\n\n\n

          A simple immediate-release oral generic that qualifies for a biowaiver costs about $2.43 million in direct spending and takes 58.9 months to reach approval in the ERG model. [1] The model assumes no patent challenge, no REMS, and no pre-approval inspection. [1]<\/p>\n\n\n\n

          What does a simple oral generic cost, stage by stage?<\/strong><\/h3>\n\n\n\n
          Development stage<\/th>Direct cost<\/th>Duration (months)<\/th>Share of direct cost (analysis)<\/th>Expected capitalized cost<\/th><\/tr><\/thead>
          1. R&D to establish API equivalence<\/td>$1,000,000<\/td>5.5<\/td>41.2%<\/td>$2,824,509<\/td><\/tr>
          2. Formulation development<\/td>$350,000<\/td>21.0<\/td>14.4%<\/td>$807,918<\/td><\/tr>
          3. In vitro testing of formulation<\/td>$30,000<\/td>1.0<\/td>1.2%<\/td>$57,428<\/td><\/tr>
          4. Initial stability testing<\/td>$100,000<\/td>1.0<\/td>4.1%<\/td>$171,024<\/td><\/tr>
          6. Biobatch manufacturing<\/td>$525,000<\/td>2.0<\/td>21.6%<\/td>$843,636<\/td><\/tr>
          12. ANDA preparation and submission (biowaiver)<\/td>$421,899<\/td>28.4<\/td>17.4%<\/td>$576,973<\/td><\/tr>
          Total<\/td>$2,426,899<\/td>58.9<\/td>100%<\/td>$5,281,488<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Source: ERG Table 2 [1]. Share-of-cost column is our calculation. Stage numbers follow ERG; stages 5, 7, 8, 9, 10, 13, and 15 do not apply to this pathway.<\/p>\n\n\n\n

          Stage 1: R&D to establish API equivalence<\/strong><\/h4>\n\n\n\n

          Stage 1 costs $1,000,000 and lasts 5.5 months. [1] It is the largest single line, at 41.2% of direct cost. The model gives it a 90% chance of success. [1]<\/p>\n\n\n\n

          Stage 2: Formulation development<\/strong><\/h4>\n\n\n\n

          Formulation takes 21.0 months, the longest stage before the filing phase. [1] It costs $350,000, or 14.4% of direct cost. [1] Time, not cash, is its main cost.<\/p>\n\n\n\n

          Stage 6: Biobatch manufacturing<\/strong><\/h4>\n\n\n\n

          ERG describes biobatches as three batches of about 100,000 doses each, made to match the planned commercial product. [1] The stage costs $525,000 and lasts 2.0 months. [1]<\/p>\n\n\n\n

          Stage 12: ANDA preparation and submission<\/strong><\/h4>\n\n\n\n

          Stage 12 costs $421,899. It includes a modeled FDA user fee of $371,899 and $50,000 for preparation. [1] Analysis: the fee is 88.1% of this stage and 15.3% of total direct cost. The FY2027 ANDA fee alone is $375,684, which is 1.0% above ERG’s user fee line, before any facility fee. [3] ERG built its line from a different fee mix, so treat that comparison as approximate.<\/p>\n\n\n\n

          Why does expected cost exceed direct cost?<\/strong><\/h3>\n\n\n\n

          ERG divides each stage’s cost by the chance that a project starting that stage reaches launch. It then adds the cost of capital at 8.82% per year, net of inflation. [1] Stage 1 shows the effect. Only 53% of projects that start it reach launch, and the money goes out first. A $1,000,000 stage becomes $2,824,509 in expected cost, a multiple of 2.82. [1] Analysis: across the full pathway, the multiple is 2.18.<\/p>\n\n\n\n

          A discrepancy in the source report<\/strong><\/h3>\n\n\n\n

          The ERG text says the average cash outlay for this example is “around $2.6 million” and that expected cost is $6.5 million, “about 2.5 times higher.” [1] Table 2 in the same report totals $2,426,899 and $5,281,488. [1] The stage lines add up to the table totals, so we use the table. If you quote ERG, quote the table and name the table.<\/p>\n\n\n\n

          How long does it take to develop a generic drug?<\/strong><\/h3>\n\n\n\n

          The simple-oral pathway totals 58.9 months in the model, or 4.9 years (analysis). [1] First-cycle approval is a major driver. ERG puts the baseline first-cycle approval rate near 20%. Raising it to 66% would cut time to market by about 13 months and expected capitalized cost by $3.5 million across ANDA types. [1]<\/p>\n\n\n\n

          How Much Does a Bioequivalence Study Cost?<\/strong><\/h2>\n\n\n\n

          A healthy-volunteer pivotal BE study costs from $2,000 to $27,000 per subject in the ERG model, depending on product type. [1] A patient study costs from $3,000 to $54,000 per subject. [1] The number of subjects matters as much as the rate.<\/p>\n\n\n\n

          What does a pivotal BE study cost by product type?<\/strong><\/h3>\n\n\n\n
          Product type<\/th>Healthy-volunteer study: subjects x cost per subject<\/th>Modeled cost (analysis)<\/th>Clinical endpoint study: subjects x cost per subject<\/th>Modeled cost (analysis)<\/th>Ratio (analysis)<\/th><\/tr><\/thead>
          Small molecule (simple)<\/td>50 x $2,000<\/td>$100,000<\/td>75 x $3,000<\/td>$225,000<\/td>2.25<\/td><\/tr>
          Topical<\/td>75 x $19,000<\/td>$1,425,000<\/td>140 x $38,000<\/td>$5,320,000<\/td>3.73<\/td><\/tr>
          Narrow therapeutic index<\/td>30 x $18,000<\/td>$540,000<\/td>45 x $27,000<\/td>$1,215,000<\/td>2.25<\/td><\/tr>
          Inhaler<\/td>50 x $25,000<\/td>$1,250,000<\/td>900 x $50,000<\/td>$45,000,000<\/td>36.0<\/td><\/tr>
          Liposome, dendrimer, polymeric micelle<\/td>30 x $15,000<\/td>$450,000<\/td>45 x $30,000<\/td>$1,350,000<\/td>3.0<\/td><\/tr>
          Iron carbohydrate complex<\/td>30 x $23,000<\/td>$690,000<\/td>45 x $46,000<\/td>$2,070,000<\/td>3.0<\/td><\/tr>
          Glatiramoid<\/td>75 x $27,000<\/td>$2,025,000<\/td>900 x $54,000<\/td>$48,600,000<\/td>24.0<\/td><\/tr>
          Ophthalmic emulsion<\/td>75 x $27,000<\/td>$2,025,000<\/td>900 x $54,000<\/td>$48,600,000<\/td>24.0<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Source: subject counts and per-subject costs from ERG Table 4 [1]; products are the model’s drug types; multiplication and ratios are our calculations. A clinical endpoint study applies only where FDA requires one. ERG cites a $45 million, 900-subject inhaled-drug study from Shur (2019), which matches the inhaler row. [1]<\/p>\n\n\n\n

          Healthy-volunteer studies vs. clinical endpoint studies<\/strong><\/h3>\n\n\n\n

          Healthy-volunteer studies measure drug levels in blood. FDA permits them when blood levels predict effect. Clinical endpoint studies enroll patients and compare treatment effects. They apply to locally acting products such as topicals, ophthalmics, and inhalers. [1] The gap is small for simple tablets (2.25 times) and very large for inhalers (36 times) and glatiramoids (24 times). This is the main reason complex generics cost so much more to develop. [1]<\/p>\n\n\n\n

          U.S. sites vs. India sites<\/strong><\/h4>\n\n\n\n

          Industry representatives told ERG that studies in India cost 40% to 50% less than U.S. studies. ERG modeled India costs at 60% of U.S. costs. [1]<\/p>\n\n\n\n

          How often do BE studies fail?<\/strong><\/h4>\n\n\n\n

          ERG’s average pivotal BE success rate ranges from 50% to 65%, depending on drug type. A pilot study raises the conditional success rate of the pivotal study by 25%. [1] DrugPatentWatch’s own cost guide gives a broader estimate of $500,000 to $3 million per BE study. [13] That figure is a secondary estimate. The ERG per-subject build-up is the primary reference.<\/p>\n\n\n\n

          Do biowaivers cut generic drug development cost?<\/strong><\/h3>\n\n\n\n

          Yes. ERG estimates that wider use of biowaivers would cut time to market by 10.6 months (11.8%) and cut expected capitalized cost by as much as 66.9%. [1] FDA allows a biowaiver only where in vitro tests can stand in for human studies.<\/p>\n\n\n\n

          Simple vs. Complex Generics: Where Does Cost Concentrate?<\/strong><\/h2>\n\n\n\n

          Cost concentrates in two places: bioequivalence studies and failure risk. Complex products also take longer and fail more often at early stages. [1]<\/p>\n\n\n\n

          Why does one inhaler study cost $45 million?<\/strong><\/h3>\n\n\n\n

          An inhaled drug acts in the lung, so blood levels may not show equivalence. FDA may require a comparative clinical endpoint study. Recruiting patients is hard. Studies need a placebo group and extra subjects to cover dropouts. [1] ERG reports 900 subjects at about $50,000 each. [1]<\/p>\n\n\n\n

          Can FDA guidance lower the cost of a complex generic?<\/strong><\/h3>\n\n\n\n

          ERG estimates that a product-specific guidance (PSG) can save “several years” of development. It puts the average saving at 22.3% of expected capitalized cost, or $25.9 million. [1] Analysis: that implies a baseline near $116 million for the complex products in that estimate. ERG counted 57 planned new PSGs for complex generics as of May 19, 2021. [1]<\/p>\n\n\n\n

          What share of ANDAs are for injectable, ophthalmic, or otic products?<\/strong><\/h3>\n\n\n\n

          In FY2020, FDA received 830 ANDAs. Of these, 233 were for parenteral, otic, or ophthalmic drugs. [1] Analysis: that is 28.1%. These products must contain the same inactive ingredients in the same concentration as the brand product, with limited exceptions. [1] ERG estimates that full ingredient disclosure could cut development cost by $3.35 million on average for otic and ophthalmic generics. [1]<\/p>\n\n\n\n

          What Does FDA Charge a Generic Applicant in FY2027?<\/strong><\/h2>\n\n\n\n

          For FY2027, the ANDA fee is $375,684 and the drug master file (DMF) fee is $109,899. [3] Facility fees run from $39,680 for a domestic API site to $245,033 for a foreign finished-dosage-form site. [3] The fiscal year began on October 1, 2026.<\/p>\n\n\n\n

          GDUFA III fee table: FY2026 vs. FY2027<\/strong><\/h3>\n\n\n\n
          Fee category<\/th>FY2026<\/th>FY2027<\/th>Change (analysis)<\/th><\/tr><\/thead>
          ANDA<\/td>$358,247<\/td>$375,684<\/td>+4.9%<\/td><\/tr>
          DMF<\/td>$102,584<\/td>$109,899<\/td>+7.1%<\/td><\/tr>
          Domestic API facility<\/td>$43,549<\/td>$39,680<\/td>-8.9%<\/td><\/tr>
          Foreign API facility<\/td>$58,549<\/td>$54,680<\/td>-6.6%<\/td><\/tr>
          Domestic FDF facility<\/td>$238,943<\/td>$230,033<\/td>-3.7%<\/td><\/tr>
          Foreign FDF facility<\/td>$253,943<\/td>$245,033<\/td>-3.5%<\/td><\/tr>
          Domestic CMO facility<\/td>$57,346<\/td>$55,208<\/td>-3.7%<\/td><\/tr>
          Foreign CMO facility<\/td>$72,346<\/td>$70,208<\/td>-3.0%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Sources: Federal Register notices for FY2026 and FY2027 [9][3]. Percent changes are our calculations. FDF means finished dosage form. CMO means contract manufacturing organization.<\/p>\n\n\n\n

          Program fees by company size<\/strong><\/h4>\n\n\n\n

          FDA also charges an annual generic drug applicant program fee. For FY2027 it is $1,927,291 for a large operation, $770,916 for a medium operation, and $192,729 for a small business. [3] Analysis: the medium fee is 40.0% of the large fee, and the small fee is 10.0%.<\/p>\n\n\n\n

          DMF and facility fees<\/strong><\/h4>\n\n\n\n

          The DMF fee rose 7.1% while every facility fee fell. [3][9] The API facility fee for a foreign site fell 6.6%. [3][9]<\/p>\n\n\n\n

          Does it cost more to make a generic abroad? The foreign facility surcharge<\/strong><\/h3>\n\n\n\n

          Yes, by a fixed $15,000 per facility in each category. In FY2027, a foreign API facility pays $54,680 against $39,680 for a domestic one. A foreign FDF facility pays $245,033 against $230,033. A foreign CMO facility pays $70,208 against $55,208. [3] Analysis: the gap is exactly $15,000 in all three, and it was also $15,000 in FY2026. [9] The surcharge is small next to the price gaps that drive sourcing choices.<\/p>\n\n\n\n

          How fast are GDUFA fees rising?<\/strong><\/h3>\n\n\n\n

          The ANDA fee was $321,920 in FY2025, $358,247 in FY2026, and $375,684 in FY2027. [8][9][3] Analysis: that is +11.3% and then +4.9%, or +16.7% over two years. FDA’s base revenue target for the program rose from $638,961,803 in FY2026 to $670,899,031 in FY2027, up 5.0% (analysis). [9][10] The per-ANDA fee depends on expected submissions. FDA estimated 618 new ANDAs for FY2026, down from 651 for FY2025. [11] Fewer filings push the per-filing fee up. GDUFA III covers FY2023 through FY2027, so Congress must reauthorize the program next. [8]<\/p>\n\n\n\n

          Fees are visible but not decisive. ERG found that a 50% cut in the ANDA fee would lower expected capitalized cost by only 1.2%. [1]<\/p>\n\n\n\n

          What Does Paragraph IV Patent Litigation Add to Generic Drug Cost?<\/strong><\/h2>\n\n\n\n

          ERG calls litigation potentially the generic company’s greatest expense, but the cited sources give no single cost figure. [1] A suit filed within 45 days of a Paragraph IV notice triggers a stay of FDA approval, generally for 30 months. [1] The reward for winning the race is 180-day exclusivity.<\/p>\n\n\n\n

          Who wins Paragraph IV cases?<\/strong><\/h3>\n\n\n\n
          Patent type challenged<\/th>Cases<\/th>Brand win<\/th>Generic win<\/th>Settled<\/th><\/tr><\/thead>
          Drug substance<\/td>33<\/td>18 (55%)<\/td>1 (3%)<\/td>14 (42%)<\/td><\/tr>
          Method of use<\/td>47<\/td>9 (19%)<\/td>16 (33%)<\/td>22 (46%)<\/td><\/tr>
          Drug product (formulation only)<\/td>35<\/td>1 (3%)<\/td>25 (71%)<\/td>9 (26%)<\/td><\/tr>
          Overall<\/td>115<\/td>28 (24%)<\/td>42 (37%)<\/td>45 (39%)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Source: Grabowski et al. (2017), top quintile of drugs by U.S. sales, 1994 to 2006, as reproduced in ERG Table 6 [1].<\/p>\n\n\n\n

          Analysis: the brand won or settled 32 of 33 drug-substance cases (97%). Generics won or settled 34 of 35 formulation-only cases (97%). A formulation patent is far weaker than a compound patent. An earlier FTC report found that generics prevailed in 73% of cases decided by a court between 1992 and 2000. [1] The two datasets differ in scope. A separate study of 274 Paragraph IV cases found 18% uncontested, 36% settled before decision, and 46% litigated to decision. [1]<\/p>\n\n\n\n

          Developers screen these variables with Orange Book listings, patent expiry dates, and litigation records. DrugPatentWatch compiles that patent and exclusivity information for U.S. drugs. Confirm any date you plan to rely on against the FDA Orange Book and the court docket.<\/p>\n\n\n\n

          What is 180-day exclusivity worth?<\/strong><\/h3>\n\n\n\n

          ERG states that 180-day exclusivity can supply 90% or more of a generic product’s total lifetime revenue. [1] The evidence is mixed on the first year. ERG found no consistently large revenue edge over non-exclusive entrants in comparable markets, with a possible value of up to 29.0% of month-6 sales for one added month of exclusivity. [1]<\/p>\n\n\n\n

          Authorized generics and product hopping<\/strong><\/h3>\n\n\n\n

          Authorized generics<\/strong><\/h4>\n\n\n\n

          The first-to-file generic’s dollar market share is 7% higher on average when no AG competes during its 180 days. First-year revenue would be about 5% higher, and the expected net present value of the project would rise 10.9%. [1]<\/p>\n\n\n\n

          Product hopping<\/strong><\/h4>\n\n\n\n

          ERG studied Pennsaid (diclofenac sodium 1.5% topical solution), Doryx (doxycycline hyclate delayed-release tablets), and Copaxone (glatiramer acetate). It found that a brand’s switch to a newly patented version could cut units sold by the first-to-file generic and later entrants by up to 29% on average in the first year. [1]<\/p>\n\n\n\n

          What Does It Cost to Manufacture a Generic Drug?<\/strong><\/h2>\n\n\n\n

          We found no primary public dataset that gives per-unit manufacturing cost for U.S. generics. We can document what shapes it: where API and finished doses come from, what FDA charges for facilities, and what product complexity adds.<\/p>\n\n\n\n

          Where do generic APIs and injectables come from?<\/strong><\/h3>\n\n\n\n

          USP reports that more than half of injectables are made outside the United States, mostly in India and the EU. India is the sole manufacturer of more than 25% of sterile injectables in shortage. [5] A USP presentation also described production of APIs and sterile injectables as heavily concentrated in India and China. [15] DrugPatentWatch’s cost guide calls API the largest and most volatile line in a generic’s cost of goods sold. [13] That is the guide’s assessment. We did not find a primary dataset that gives the API share.<\/p>\n\n\n\n

          What do facility compliance steps add?<\/strong><\/h3>\n\n\n\n

          ERG counts $100,000 for a REMS submission and $20,000 for a pre-approval inspection in its model, where those steps apply. [1] FDA facility fees recur each fiscal year, from $39,680 to $245,033 per site in FY2027. [3] These figures are small beside plant capital cost, which our sources do not report.<\/p>\n\n\n\n

          What does public data not show?<\/strong><\/h3>\n\n\n\n

          It does not show cost of goods per tablet or per vial, plant capital cost, or yield loss. Company filings report these only in blended form, and generic makers often sell brands and biosimilars too. Any article that quotes a precise cost per pill without a source is guessing.<\/p>\n\n\n\n

          Why are sterile injectables more fragile?<\/strong><\/h4>\n\n\n\n

          USP names manufacturing complexity as one of four factors that raise shortage risk. Sterile injectables are its main example. [14] Low prices are another factor, and the two combine. [14]<\/p>\n\n\n\n

          Why Do Generic Prices Fall So Fast After Launch?<\/strong><\/h2>\n\n\n\n

          Prices fall because each new entrant competes on price for the same prescriptions. FDA found that prices keep dropping as the number of generic producers rises. [12]<\/p>\n\n\n\n

          What do FDA price data show by number of competitors?<\/strong><\/h3>\n\n\n\n
          Generic producers<\/th>Price below pre-entry brand price (AMP)<\/th>Price below pre-entry brand price (invoice)<\/th>Share of brand price remaining, AMP (analysis)<\/th><\/tr><\/thead>
          1<\/td>39%<\/td>31%<\/td>61%<\/td><\/tr>
          2<\/td>54%<\/td>44%<\/td>46%<\/td><\/tr>
          4<\/td>79%<\/td>73%<\/td>21%<\/td><\/tr>
          6 or more<\/td>More than 95%<\/td>More than 95%<\/td>Under 5%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Sources: FDA analysis of products with initial generic entry in 2015 to 2017 [12][4]. AMP means average manufacturer price reported to CMS. The invoice series reflects pharmacy acquisition prices.<\/p>\n\n\n\n

          Analysis: the second entrant cuts the remaining price by 25% (from 61% to 46% of the brand price). Going from two to four producers cuts it by a further 54%.<\/p>\n\n\n\n

          Entry is also thin in many markets. A study cited by ERG found that about 10% of brand drugs with expired patents have no generic competitor and 25% have one. [1] Another cited study found a median of two to three generic makers per molecule. [1]<\/p>\n\n\n\n

          How do prices compare inside and outside the 180-day period?<\/strong><\/h3>\n\n\n\n
          Generic competitors<\/th>Price during 180-day exclusivity (share of pre-entry brand price)<\/th>Price outside exclusivity<\/th><\/tr><\/thead>
          1<\/td>74%<\/td>43%<\/td><\/tr>
          2<\/td>64%<\/td>37%<\/td><\/tr>
          3<\/td>38%<\/td>29%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Source: Olson and Wendling (2018), as reproduced in ERG Table 3 [1].<\/p>\n\n\n\n

          Analysis: from one to three competitors, the price falls 48.6% during exclusivity (74% to 38%) and 32.6% outside it (43% to 29%). The exclusivity premium shrinks fast once a third generic enters.<\/p>\n\n\n\n

          Per-Prescription Economics: What Do Payers Actually Spend?<\/strong><\/h2>\n\n\n\n

          At reported totals, the U.S. spent about $26.50 per generic prescription in 2025 and about $1,658 per brand prescription. [2] The ratio is 62.6 to 1 (analysis).<\/p>\n\n\n\n

          How did generic and brand spending change from 2024 to 2025?<\/strong><\/h3>\n\n\n\n
          Metric<\/th>2024<\/th>2025<\/th>Change (analysis)<\/th><\/tr><\/thead>
          Generic prescriptions<\/td>3.9 billion<\/td>4 billion<\/td>+2.6%<\/td><\/tr>
          Generic spending<\/td>$98 billion<\/td>$106 billion<\/td>+8.2%<\/td><\/tr>
          Generic spending per prescription<\/td>$25.13<\/td>$26.50<\/td>+5.5%<\/td><\/tr>
          Brand prescriptions<\/td>435 million<\/td>485 million<\/td>+11.5%<\/td><\/tr>
          Brand spending<\/td>$700 billion<\/td>$804 billion<\/td>+14.9%<\/td><\/tr>
          Brand spending per prescription<\/td>$1,609<\/td>$1,658<\/td>+3.0%<\/td><\/tr>
          Brand-to-generic per-prescription ratio<\/td>64.0<\/td>62.6<\/td>Not applicable<\/td><\/tr>
          Generic share of prescriptions<\/td>90%<\/td>89%<\/td>-1 point<\/td><\/tr>
          Generic share of Rx drug spending<\/td>12%<\/td>11.6%<\/td>-0.4 points<\/td><\/tr>
          Reported savings from generics and biosimilars<\/td>$467 billion<\/td>$496 billion<\/td>+6.2%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Sources: AAM and IQVIA Institute reports for 2024 and 2025 data [7][2]. Per-prescription figures and changes are our calculations from rounded totals, so treat them as approximate.<\/p>\n\n\n\n

          Generic spending per prescription rose faster than brand spending per prescription in 2025. Brand volume grew faster than generic volume. The cited reports do not explain either shift. AAM also reported that generics and biosimilars were 1.2% of all U.S. health care spending in 2024. [7]<\/p>\n\n\n\n

          Why Do Low-Cost Generics Go Into Shortage?<\/strong><\/h2>\n\n\n\n

          They go into shortage because the lowest-priced products leave little margin for plant upkeep or spare capacity. USP found that generic injectables in shortage have much lower average prices than those not in shortage. [5][15]<\/p>\n\n\n\n

          What does the latest USP shortage data show?<\/strong><\/h3>\n\n\n\n

          USP counted 71 shortages in 2025, down from 98 in 2024 (a 27.6% drop, analysis). But the average duration reached a record five years, more than a year longer than in 2024. [5] Of the drugs in shortage, 71% were sterile injectables. Almost half of those were priced between zero and five dollars per unit. [5] USP’s 2023 report found that sterile injectables in shortage averaged nearly 8.5 times less in price than injectables not in shortage. [15]<\/p>\n\n\n\n

          Are manufacturers leaving the market?<\/strong><\/h3>\n\n\n\n

          Discontinuations rose 60% in 2025 to their highest level since 2019. More than a third of injectables discontinued in 2025 sold at $15 or below. [5] A USP official said the current system has been optimized for efficiency and cost over resilience. [5] USP’s first shortage report named low prices and contract failures as sources of fragility. [14]<\/p>\n\n\n\n

          Generic Drug Profitability: What Do Margins Look Like?<\/strong><\/h2>\n\n\n\n

          Public company data mixes generics with biosimilars and brands, so it cannot give a clean generics-only margin. Sandoz is one useful reference.<\/p>\n\n\n\n

          What did Sandoz report for FY2025?<\/strong><\/h3>\n\n\n\n

          Sandoz reported FY2025 net sales of $11.1 billion and a core EBITDA margin of 21.7%, up 160 basis points. Biosimilar sales grew 13% at constant currency and generics grew 2%. [16] Analysis: 21.7% of $11.1 billion is about $2.4 billion of core EBITDA. In the first half of 2025, generics were 71% of net sales and biosimilars 29%. [16] The margin therefore blends two businesses. The 2-point gap between biosimilar and generic growth suggests mix explains part of the margin gain, and Sandoz itself credits favorable sales mix among other causes. [16]<\/p>\n\n\n\n

          How Do Section 232 Tariffs Affect Generic Drug Costs?<\/strong><\/h2>\n\n\n\n

          Today they do not apply to generics. The April 2, 2026 proclamation imposed tariffs of up to 100% on patented pharmaceuticals and their ingredients, and expressly excluded generics, biosimilars, and their ingredients. [6]<\/p>\n\n\n\n

          What does the proclamation cover and when did it start?<\/strong><\/h3>\n\n\n\n

          Tariffs took effect July 31, 2026 for large companies listed in Annex III and September 29, 2026 for all other importers. US-origin pharmaceutical products are not subject to the tariffs. [6] By September 29, 2026, tariffs applied to all branded drug companies, not only the largest. [17]<\/p>\n\n\n\n

          When could the generic exemption change?<\/strong><\/h3>\n\n\n\n

          Commerce will reassess the generic exclusion within one year of the proclamation, which puts the deadline near April 2027. [6] Managed Healthcare Executive reports that the president said in July that imported generics will face no tariff through July 2028, and that generic tariffs are set to start after that. [17] We could not confirm a signed proclamation for generics as of October 7, 2026. Check the Federal Register before you plan around any date.<\/p>\n\n\n\n

          Scenario analysis: what could a generic tariff do to margin?<\/strong><\/h3>\n\n\n\n

          Assumptions<\/strong><\/h4>\n\n\n\n

          These inputs are hypothetical. They are not data and not a forecast. Net price is $1.00 per unit. Cost of goods is 60% of price ($0.60). Half of cost of goods, or $0.30, is imported content that a tariff would reach. The starting gross margin is 40%.<\/p>\n\n\n\n

          Result<\/strong><\/h4>\n\n\n\n
          Tariff on imported content<\/th>Added cost per unit<\/th>Gross margin<\/th>Price rise needed to restore 40% margin<\/th><\/tr><\/thead>
          0%<\/td>$0.000<\/td>40.0%<\/td>0%<\/td><\/tr>
          10%<\/td>$0.030<\/td>37.0%<\/td>5.0%<\/td><\/tr>
          25%<\/td>$0.075<\/td>32.5%<\/td>12.5%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Source: our arithmetic on the stated assumptions. Margin equals 1.00 minus 0.60 minus (tariff x 0.30).<\/p>\n\n\n\n

          The point is the mechanism. In a market where price falls below 5% of the pre-entry brand price, a 5% to 12.5% price rise is hard to pass on, and shortage risk grows where margins are already thin. [4][5]<\/p>\n\n\n\n

          What This Means for Generic Entry, Brand Manufacturers, and Payers<\/strong><\/h2>\n\n\n\n

          What this means for generic entry<\/strong><\/h3>\n\n\n\n

          Entry pays when expected revenue exceeds expected capitalized cost. For the simple oral product above, that bar is $5.28 million in 2020 dollars. [1] Complex products raise the bar through BE study cost and failure risk. Developers who can use a biowaiver or an existing PSG have the largest cost advantage. [1]<\/p>\n\n\n\n

          What this means for brand manufacturers<\/strong><\/h3>\n\n\n\n

          Generic cost sets a floor on how fast brand revenue falls. A drug-substance patent is the strongest defense: brands won or settled 32 of 33 such cases in the Grabowski sample. [1] Formulation patents hold up poorly. Authorized generics and product hops reduce first-to-file generic revenue, and ERG measured effects of 7 points of share and up to 29% of units. [1]<\/p>\n\n\n\n

          What this means for payers<\/strong><\/h3>\n\n\n\n

          Savings come from volume and competition, not from low unit cost alone. AAM reports $496 billion in savings from generics and biosimilars in 2025. [2] The same low prices carry supply risk in sterile injectables. Contracts that reward reliability, not only the lowest bid, address that risk. This is a policy view that USP and others have raised, and it is not a measured result. [5]<\/p>\n\n\n\n

          Generic Drug Cost Timeline, 2021 to 2028<\/strong><\/h2>\n\n\n\n
          Date<\/th>Event<\/th>Status<\/th>Source<\/th><\/tr><\/thead>
          Dec. 31, 2021<\/td>ERG delivers HHS report on generic development cost<\/td>Documented<\/td>[1]<\/td><\/tr>
          Jul. 30, 2025<\/td>FDA publishes FY2026 GDUFA fees; ANDA fee $358,247<\/td>Documented<\/td>[9]<\/td><\/tr>
          Feb. 2026<\/td>Sandoz reports FY2025 core EBITDA margin of 21.7%<\/td>Documented<\/td>[16]<\/td><\/tr>
          Apr. 2, 2026<\/td>Section 232 proclamation on patented pharmaceuticals; generics excluded<\/td>Documented<\/td>[6]<\/td><\/tr>
          Jun. 2026<\/td>USP shortage report: 71 shortages in 2025, five-year average duration<\/td>Documented<\/td>[5]<\/td><\/tr>
          Jul. 30, 2026<\/td>FDA publishes FY2027 GDUFA fees; ANDA fee $375,684<\/td>Documented<\/td>[3]<\/td><\/tr>
          Jul. 31, 2026<\/td>Tariffs start for Annex III companies<\/td>Documented<\/td>[6]<\/td><\/tr>
          Sep. 29, 2026<\/td>Tariffs start for all other importers of patented drugs<\/td>Documented<\/td>[6][17]<\/td><\/tr>
          Sep. 30, 2027<\/td>GDUFA III covers FY2023 through FY2027<\/td>Scheduled in statute<\/td>[8]<\/td><\/tr>
          About Apr. 2027<\/td>Commerce reassessment of generic exclusion due<\/td>Scheduled (estimated from one-year deadline)<\/td>[6]<\/td><\/tr>
          Jul. 2028<\/td>Stated end of the no-tariff period for imported generics<\/td>Announced, not confirmed as enacted<\/td>[17]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Key Takeaways<\/strong><\/h2>\n\n\n\n
            \n
          • A simple oral generic has a direct development cost of $2,426,899 and an expected cost of $5,281,488 in the ERG model (2020 dollars). [1]<\/li>\n\n\n\n
          • The report text and its table disagree on those totals. Use the table. [1]<\/li>\n\n\n\n
          • BE study cost ranges from $100,000 for a simple tablet to about $45 million for an inhaler clinical endpoint study (model figures). [1]<\/li>\n\n\n\n
          • The FY2027 ANDA fee is $375,684, up 16.7% from FY2025. [3][8]<\/li>\n\n\n\n
          • Generic prices fall to under 5% of the pre-entry brand price once six or more makers compete. [4]<\/li>\n\n\n\n
          • Generics were 89% of prescriptions and 11.6% of prescription drug spending in 2025. [2]<\/li>\n\n\n\n
          • Sterile injectables are 71% of drugs in shortage, and shortages last five years on average. [5]<\/li>\n\n\n\n
          • Generics are excluded from the Section 232 pharmaceutical tariffs for now, and the exclusion is under review. [6]<\/li>\n<\/ul>\n\n\n\n

            FAQ<\/strong><\/h2>\n\n\n\n

            How much does it cost to file an ANDA with FDA in FY2027?<\/strong><\/h3>\n\n\n\n

            The ANDA fee is $375,684. [3] Applicants also pay facility fees and, in some cases, a DMF fee of $109,899 and an annual program fee. [3] ERG adds $50,000 to $100,000 for preparing the filing. [1]<\/p>\n\n\n\n

            How long does a simple generic take to develop?<\/strong><\/h3>\n\n\n\n

            The ERG model gives 58.9 months, or 4.9 years, for a simple oral product on the biowaiver pathway. [1] A first-cycle approval rate near 20% adds delay. [1]<\/p>\n\n\n\n

            Is a bioequivalence study always required?<\/strong><\/h3>\n\n\n\n

            No. A product that qualifies for a biowaiver can use in vitro tests instead. ERG estimates biowaivers cut time to market by 10.6 months and expected capitalized cost by as much as 66.9%. [1]<\/p>\n\n\n\n

            Why do generic makers challenge brand patents?<\/strong><\/h3>\n\n\n\n

            The first filer of a Paragraph IV challenge is generally eligible for 180-day exclusivity, which ERG says can supply 90% or more of a generic product’s lifetime revenue. [1] Authorized generics reduce that value. [1]<\/p>\n\n\n\n

            How many competitors does it take to push prices down by more than 95%?<\/strong><\/h3>\n\n\n\n

            Six or more generic producers, based on FDA’s analysis of products with first generic entry in 2015 to 2017. [4]<\/p>\n\n\n\n

            Where are generic sterile injectables made?<\/strong><\/h3>\n\n\n\n

            More than half of injectables are made outside the United States, mostly in India and the EU. India is the only manufacturer of more than 25% of sterile injectables in shortage. [5]<\/p>\n\n\n\n

            Do tariffs apply to generic drugs today?<\/strong><\/h3>\n\n\n\n

            No. The April 2, 2026 Section 232 proclamation excludes generics, biosimilars, and their ingredients. [6] Commerce must reassess within one year. [6]<\/p>\n\n\n\n

            Why do generic makers leave markets?<\/strong><\/h3>\n\n\n\n

            ERG notes that generic firms re-evaluate their position continuously and may exit if sales volume is too low to be profitable. [1] USP counted a 60% rise in discontinuations in 2025. [5]<\/p>\n\n\n\n

            How much do generics save the U.S. health system?<\/strong><\/h3>\n\n\n\n

            AAM and IQVIA report $496 billion in savings from generics and biosimilars in 2025, up from $467 billion in 2024. [2][7]<\/p>\n\n\n\n

            How can I check patent and exclusivity status before I model a generic launch?<\/strong><\/h3>\n\n\n\n

            Start with the FDA Orange Book and court dockets. DrugPatentWatch compiles patent expiry dates, exclusivity, and generic entry information in one place and can speed up screening. Verify any date you rely on against the primary record.<\/p>\n\n\n\n

            References<\/strong><\/h2>\n\n\n\n
              \n
            1. Sertkaya, A., Lord, A., & Berger, C. (2021, December 31). Cost of generic drug development and approval<\/em> (Final report). Eastern Research Group for the Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/66e13df52a6d314ba4e10c8e55b68b4b\/cost-of-generic-drugs-erg.pdf<\/li>\n\n\n\n
            2. Association for Accessible Medicines. (2026). 2026 U.S. generic & biosimilar medicines savings report<\/em> (in partnership with the IQVIA Institute). https:\/\/accessiblemeds.org\/?p=5117<\/li>\n\n\n\n
            3. U.S. Food and Drug Administration. (2026, July 30). Generic drug user fee rates for fiscal year 2027. Federal Register<\/em>. https:\/\/www.federalregister.gov\/documents\/2026\/07\/30\/2026-15343\/generic-drug-user-fee-rates-for-fiscal-year-2027<\/li>\n\n\n\n
            4. European Pharmaceutical Review. (2019, December 16). Report links greater generic competition and lower generic drug prices (summarizing FDA’s December 2019 analysis). https:\/\/www.europeanpharmaceuticalreview.com\/?p=108189<\/li>\n\n\n\n
            5. Bioprocess International. (2026, June 18). Independent US body finds drug shortages are lasting longer as reliability dwindles (reporting USP’s annual drug shortages report). https:\/\/www.bioprocessintl.com\/global-markets\/independent-us-body-finds-drug-shortages-are-lasting-longer-as-reliability-dwindles<\/li>\n\n\n\n
            6. JD Supra. (2026). President Trump imposes Section 232 tariffs on pharmaceuticals: What importers need to know. https:\/\/www.jdsupra.com\/legalnews\/president-trump-imposes-section-232-9642137\/<\/li>\n\n\n\n
            7. Association for Accessible Medicines. (2025). 2025 U.S. generic & biosimilar medicines savings report<\/em> (in partnership with the IQVIA Institute). https:\/\/accessiblemeds.org\/resources\/blog\/2025-savings-report\/<\/li>\n\n\n\n
            8. U.S. Food and Drug Administration. (n.d.). Generic Drug User Fee Amendments. https:\/\/www.fda.gov\/gdufa<\/li>\n\n\n\n
            9. U.S. Food and Drug Administration. (2025, July 30). Generic drug user fee rates for fiscal year 2026. Federal Register<\/em>, 90(144). https:\/\/www.govinfo.gov\/content\/pkg\/FR-2025-07-30\/html\/2025-14411.htm<\/li>\n\n\n\n
            10. Regulatory Affairs Professionals Society. (2026). FDA unveils FY 2027 user fee rates. https:\/\/www.raps.org\/resource\/fda-unveils-fy-2027-user-fee-rates.html<\/li>\n\n\n\n
            11. Lachman Consultants. (2025, July). GDUFA fee schedule for FY 2026 hits the street: Big jump in application fees. https:\/\/www.lachmanconsultants.com\/2025\/07\/gdufa-fee-schedule-for-fy-2026-hits-the-street-big-jump-in-application-fees\/<\/li>\n\n\n\n
            12. U.S. Food and Drug Administration. (2019, December). Generic competition and drug prices: New evidence linking greater generic competition and lower generic drug prices<\/em>. https:\/\/fda.gov\/media\/133509\/download<\/li>\n\n\n\n
            13. DrugPatentWatch. (n.d.). Breaking down the cost of generic drug production: Understanding the factors influencing affordability. https:\/\/www.drugpatentwatch.com\/blog\/breaking-down-the-cost-of-generic-drug-production-understanding-the-factors-influencing-affordability\/<\/li>\n\n\n\n
            14. U.S. Pharmacopeia. (n.d.). U.S. drug shortages reach decade-high and last longer (inaugural drug shortage report announcement). https:\/\/usp.org\/node\/236626<\/li>\n\n\n\n
            15. Informa Connect. (n.d.). Data show drug shortages are bigger than ever (summarizing USP’s 2023 annual drug shortage report). https:\/\/www.bioxconomy.com\/access-and-channel\/data-show-drug-shortages-are-bigger-than-ever<\/li>\n\n\n\n
            16. Sandoz. (2026, February). Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth (press release; reproduced at 1st Oncology). https:\/\/www.1stoncology.com\/blog\/?p=108889<\/li>\n\n\n\n
            17. Managed Healthcare Executive. (2026, September 29). Tariffs on patented drugs now apply to all branded drugmakers. https:\/\/www.managedhealthcareexecutive.com\/view\/tariffs-on-patented-drugs-now-apply-to-all-branded-drugmakers<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

              A simple generic tablet needs about $2.43 million in direct development spending and about 58.9 months to move from first […]<\/p>\n","protected":false},"author":1,"featured_media":39801,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-23908","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=23908"}],"version-history":[{"count":0,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23908\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39801"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=23908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=23908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=23908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}